Seelos Therapeutics is gearing up for a pilot study, in Australia, testing SLS-005 (trehalose) — its investigational therapy for people with Alzheimer’s disease — after receiving an acknowledgment letter from the country’s regulatory body for clinical trials. The letter, from the Australian Government Department of Health Therapeutic Goods Administration (TGA), was issued after the company notified the agency of its intent to conduct a pilot study of SLS-005. The TGA is responsible for regulating treatments,…
You must be logged in to read/download the full post.
The post Seelos Gears Up for Pilot Study in Australia Testing SLS-005 appeared first on BioNewsFeeds.